From: Cross-species genomic and functional analyses identify a combination therapy using a CHK1 inhibitor and a ribonucleotide reductase inhibitor to treat triple-negative breast cancer
MB231 (screen 1)
MB231 (screen 2)
Hs578T
MCF10A
ANLN
-3.275
-2.657
-2.139
-2.230
CHEK1
-2.766
-2.441
-4.719
-0.218
KIF11
-2.475
-2.231
-3.832
-2.770
RRM1
-2.637
-2.347
-2.053
-0.955
RRM2
-3.647
-2.915
-2.518
-1.348
TPX2
-1.932
-1.697
-3.864
-1.452